drugset / Trial / NCT01848171

Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism

NCT01848171

Phase 4 Unknown 700 enrolled Shandong Provincial Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Hypothyroidism is a common clinical entity which is often complicated by dyslipidemia. It is also reported increased risk for incidence of atherosclerosis and resulting coronary heart disease(CHD), heart failure(HF) and cardiovascular(CV) death. The effect of L-thyroxine replacement treatment on serum lipid and atherosclerosis is controversial in hypothyroid patients, especially in those with mild or moderate subclinical hypothyroidism. The present study was designed to investigate whether L-thyroxine replacement was effective in improving serum lipid profiles and retarding atherosclerosis progress. Studies have shown that hypothyroidism increased the risk of COVID-19 composite poor outcomes. This study also aimed to investigate whether L-thyroxine replacement therapy was effective in reducing the incidence and mortality of COVID-19, and in improving the severity of COVID-19 and COVID-19 related complications.

Timeline

Start
2013-07
Primary completion
2023-07
Completion
2023-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levothyroxine Other / unclassified 25 ug Oral
Comparator Levothyroxine Other / unclassified 50 ug Oral

Indications